Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cara Therapeutics's Enterprise Value is $-13.57 Mil.
Cara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-62.79 Mil. Therefore, Cara Therapeutics's EV-to-EBIT ratio for today is 0.22.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cara Therapeutics's Enterprise Value is $-13.57 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-62.60 Mil. Therefore, Cara Therapeutics's EV-to-EBITDA ratio for today is 0.22.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cara Therapeutics's Enterprise Value is $-13.57 Mil.
Cara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $7.14 Mil. Therefore, Cara Therapeutics's EV-to-Revenue ratio for today is -1.90.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Cara Therapeutics Enterprise Value Historical Data
The historical data trend for Cara Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cara Therapeutics's Enterprise Value
For the Biotechnology subindustry, Cara Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cara Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cara Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cara Therapeutics's current Enterprise Value is $-13.57 Mil.
Cara Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.79 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cara Therapeutics's current Enterprise Value is $-13.57 Mil.
Cara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.60 Mil.
Cara Therapeutics's current Enterprise Value is $-13.57 Mil.
Cara Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.14 Mil.
Cara Therapeutics's current Enterprise Value is $-13.57 Mil.
Cara Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cara Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CARA has been successfully added to your 